Patents by Inventor Renato Canevotti
Renato Canevotti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11420943Abstract: Disclosed are peptide or pseudopeptide derivatives containing a nitrogenous heterocyclic residue with blocking activity against the by-products of lipid oxidative stress, and in particular of unsaturated aldehydes such as malondialdehyde and 4-hydroxy-trans-2-nonenal (HNE).Type: GrantFiled: December 19, 2018Date of Patent: August 23, 2022Assignee: FLAMMA S.P.A.Inventors: GianPaolo Negrisoli, Stefania Gagliardi, Almin Silnovic, Clelia Dallanoce, Marco De Amici, Renato Canevotti
-
Publication number: 20200361875Abstract: Disclosed are peptide or pseudopeptide derivatives containing a nitrogenous heterocyclic residue with blocking activity against the by-products of lipid oxidative stress, and in particular of unsaturated aldehydes such as malondialdehyde and 4-hydroxy-trans-2-nonenal (HNE).Type: ApplicationFiled: December 19, 2018Publication date: November 19, 2020Applicant: FLAMMA S.P.A.Inventors: GianPaolo NEGRISOLI, Stefania GAGLIARDI, Almin SILNOVIC, Clelia DALLANOCE, Marco DE AMICI, Renato CANEVOTTI
-
Patent number: 10011605Abstract: The present invention relates to a process for preparation of triazolo[4,5-d] pyrimidine cyclopentane compounds of formula (I), and pharmaceutically acceptable salts thereof. The invention also provides novel compounds that can be used as intermediates in the process for preparing triazolo[4,5-d] pyrimidine cyclopentane compounds. The process and the intermediates are particularly useful for the preparation of ticagrelor and pharmaceutically acceptable salts thereof.Type: GrantFiled: June 11, 2015Date of Patent: July 3, 2018Assignee: FLAMMA SPAInventors: Anna Rencurosi, Massimo Previtali, Federico Della Negra, Francesco Mormile, Renato Canevotti
-
Publication number: 20170129898Abstract: The present invention relates to a process for preparation of triazolo[4,5-d] pyrimidine cyclopentane compounds of formula (I), and pharmaceutically acceptable salts thereof. The invention also provides novel compounds that can be used as intermediates in the process for preparing triazolo[4,5-d] pyrimidine cyclopentane compounds. The process and the intermediates are particularly useful for the preparation of ticagrelor and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: June 11, 2015Publication date: May 11, 2017Applicant: FLAMMA SPAInventors: Anna RENCUROSI, Massimo PREVITALI, Federico DELLA NEGRA, Francesco MORMILE, Renato CANEVOTTI
-
Patent number: 9085750Abstract: The conversion of a peptide aldehyde to a hydrosulfite adduct can be used to increase the aqueous solubility in the purification of the peptide aldehydes. Advantageously, this hydrosulfite adduct is itself effective as a subtilisin inhibitor and stabilizer and it can also stabilize a second enzyme if present. The hydrosulfite adduct is effective as a subtilisin inhibitor, and it maintains its inhibitory and stabilizing effect in a liquid detergent during storage. Thus, use of the hydrosulfite adduct can avoid the cost and time of converting it back to the peptide aldehyde and subsequent drying of the peptide aldehyde can be saved, and this can avoid the inconvenience of handling the peptide aldehyde in powder form or as a highly diluted aqueous solution.Type: GrantFiled: June 29, 2012Date of Patent: July 21, 2015Assignee: Novozymes A/SInventors: Lise Munch Mikkelsen, Francesco Ponzini, Roberto Bisaccia, Renato Canevotti
-
Publication number: 20140336098Abstract: The conversion of a peptide aldehyde to a hydrosulfite adduct can be used to increase the aqueous solubility in the purification of the peptide aldehydes. Advantageously, this hydrosulfite adduct is itself effective as a subtilisin inhibitor and stabilizer and it can also stabilize a second enzyme if present. The hydrosulfite adduct is effective as a subtilisin inhibitor, and it maintains its inhibitory and stabilizing effect in a liquid detergent during storage. Thus, use of the hydrosulfite adduct can avoid the cost and time of converting it back to the peptide aldehyde and subsequent drying of the peptide aldehyde can be saved, and this can avoid the inconvenience of handling the peptide aldehyde in powder form or as a highly diluted aqueous solution.Type: ApplicationFiled: June 29, 2012Publication date: November 13, 2014Applicant: Novozymes A/SInventors: Lise Munch Mikkelsen, Francesco Ponzini, Roberto Bisaccia, Renato Canevotti
-
Patent number: 8846763Abstract: A process for obtaining therapeutically active 2-[4-(3- and 2-(fluorobenzyloxy)benzylamino]propanamides, and their salts with pharmaceutically acceptable acids with high purity degree, in particular, with a content of dibenzyl derivatives impurities lower than 0.03%, preferably lower than 0.01% by weight. The process is carried out by submitting the Schiff bases intermediates 2-[4-(3- and 2-fluorobenzyloxy)benzylideneamino]propanamides to a reduction reaction with a reducing agent selected from sodium borohydride and potassium borohydride in an appropriate amount of an organic solvent selected from C1-C5 lower alkanols, allowing the formation and presence during a substantial position of the reduction reaction course of a suspension of the Schiff base into the saturated solution of the Schiff base into the same organic solvent.Type: GrantFiled: August 7, 2013Date of Patent: September 30, 2014Assignee: Newron Pharmaceuticals, S.p.A.Inventors: Elena Barbanti, Laura Faravelli, Patricia Salvati, Renato Canevotti, Francesco Ponzini
-
Patent number: 8765798Abstract: Dipeptide compounds containing a histidine residue proved to have interesting blocking activity on secondary products from lipid oxidative stress, in particular on unsaturated aldehydes such as malondialdehyde and hydroxynonenal, which are known to contribute to the inset of quite a number of chronic pathologies such as neurodegenerative, inflammatory chronic, cardiovascular diseases, diabetes complications and cataract.Type: GrantFiled: June 15, 2007Date of Patent: July 1, 2014Assignee: Flamma S.p.A.Inventors: Gianpaolo Negrisoli, Renato Canevotti
-
Publication number: 20140051758Abstract: A process for obtaining therapeutically active 2-[4-(3- and 2-(fluorobenzyloxy)benzylamino]propanamides, and their salts with pharmaceutically acceptable acids with high purity degree, in particular, with a content of dibenzyl derivatives impurities lower than 0.03%, preferably lower than 0.01% by weight. The process is carried out by submitting the Schiff bases intermediates 2-[4-(3- and 2-fluorobenzyloxy)benzylideneamino]propanamides to a reduction reaction with a reducing agent selected from sodium borohydride and potassium borohydride in an appropriate amount of an organic solvent selected from C1-C5 lower alkanols, allowing the formation and presence during a substantial position of the reduction reaction course of a suspension of the Schiff base into the saturated solution of the Schiff base into the same organic solvent.Type: ApplicationFiled: August 7, 2013Publication date: February 20, 2014Applicant: Newron Pharmaceuticals S.p.A.Inventors: Elena BARBANTI, Laura Faravelli, Patricia Salvati, Renato Canevotti, Francesco Ponzini
-
Patent number: 8623900Abstract: The present invention relates to amino alcohol derivatives of general formula I: These derivatives possess an interesting activity in that they block the secondary products of lipid oxidative stress, and are consequently suitable for therapeutic use in all disorders related with the presence of reactive carbonyl compounds.Type: GrantFiled: December 20, 2010Date of Patent: January 7, 2014Assignees: Flamma S.p.A., Universita degli Studi di MilanoInventors: Gianpaolo Negrisoli, Renato Canevotti, Massimo Previtali, Giancarlo Aldini, Marina Carini, Marica Orioli, Giulio Vistoli
-
Patent number: 8530701Abstract: A process for obtaining therapeutically active 2-[4-(3- and 2-(fluorobenzyloxy)benzylamino]-propanamides and their salts with pharmaceutically acceptable acids with a high degree of purity, i.e. with a content of dibenzyl derivatives impurities lower than 0.03% by weight. The process is carried out by submitting a Schiff base intermediate to a reduction reaction with a reducing agent in an amount of organic solvent to allow the formation (and presence during a substantial portion of the reduction reaction) of a suspension of the Schiff base.Type: GrantFiled: December 1, 2008Date of Patent: September 10, 2013Assignee: Newron Pharmaceuticals, S.p.A.Inventors: Elena Barbanti, Laura Faravelli, Patricia Salvati, Renato Canevotti, Francesco Ponzini
-
Publication number: 20120316212Abstract: The present invention relates to amino alcohol derivatives of general formula I: These derivatives possess an interesting activity in that they block the secondary products of lipid oxidative stress, and are consequently suitable for therapeutic use in all disorders related with the presence of reactive carbonyl compounds.Type: ApplicationFiled: December 20, 2010Publication date: December 13, 2012Applicants: UNIVERSITA DEGLI STUDI DI MILANO, FLAMMA S.P.A.Inventors: Gianpaolo Negrisoli, Renato Canevotti, Massimo Previtali, Giancarlo Aldini, Marina Carini, Marica Orioli, Giulio Vistoli
-
Publication number: 20100324141Abstract: A process for obtaining therapeutically active 2-[4-(3- and 2-(fluorobenzyloxy)benzylamino]-propanamides and their salts with pharmaceutically acceptable acids with a high degree of purity, i.e. with a content of dibenzyl derivatives impurities lower than 0.03% by weight. The process is carried out by submitting a Schiff base intermediate to a reduction reaction with a reducing agent in an amount of organic solvent to allow the formation (and presence during a substantial portion of the reduction reaction) of a suspension of the Schiff base.Type: ApplicationFiled: December 1, 2008Publication date: December 23, 2010Applicant: NEWRON PHARMACEUTICALS S.P.A.Inventors: Elena Barbanti, Laura Faravelli, Patricia Salvati, Renato Canevotti, Francesco Ponzini
-
Publication number: 20090306165Abstract: D-Camosine lipophilic derivatives are disclosed, characterized by higher bioavailability than L-camosine and intended for the pulmonary distribution where they can exert detoxifying activity on the cytotoxic carbonyl compounds induced by cigarette smoke.Type: ApplicationFiled: June 15, 2007Publication date: December 10, 2009Inventors: Gianpaolo Negrisoli, Renato Canevotti, massimo Previtali
-
Publication number: 20090247601Abstract: Dipeptide compounds containing a histidine residue proved to have interesting blocking activity on secondary products from lipid oxidative stress, in particular on unsaturated aldehydes such as malondialdehyde and hydroxynonenal, which are known to contribute to the inset of quite a number of chronic pathologies such as neurodegenerative, inflammatory chronic, cardiovascular diseases, diabetes complications and cataract.Type: ApplicationFiled: June 15, 2007Publication date: October 1, 2009Inventors: Gianpaolo Negrisoli, Renato Canevotti
-
Publication number: 20080206347Abstract: The invention provides methods for the adsorption of an active pharmaceutical ingredient on titianium dioxide nanoparticles which can be orally ingested allowing the drug release into the intestine without causing side effects to the upper gastrointestinal region.Type: ApplicationFiled: April 12, 2006Publication date: August 28, 2008Applicant: FLAMMA S.P.A.Inventors: Alberto Marra, Alessandro Dondoni, Carlo Alberto Bignozzi, Renato Canevotti, Negrisoli Gian Paolo, Valeria Dissette
-
Publication number: 20080194493Abstract: Disclosed are compositions containing D-carnosine as active ingredient, mixed with suitable vehicles or excipients.Type: ApplicationFiled: June 7, 2005Publication date: August 14, 2008Inventors: Giancarlo Aldini, Renato Canevotti, Gianpaolo Negrisoli
-
Patent number: 6111114Abstract: The compounds of the formula (I) wherein R is as defined in the disclosure, are prepared by bromination of compounds of the formula (II) by means of Br.sub.2 or HBr in the presence of H.sub.2 O.sub.2.Type: GrantFiled: October 19, 1999Date of Patent: August 29, 2000Assignee: Istituto Luso Farmaco D'Italia S.p.A.Inventors: Aldo Salibeni, Renato Canevotti
-
Patent number: 6096754Abstract: N-3-substituted pyrimindin-4-ones with angiotension II (AII) antagonistic activity are characterized by the presence of a heterocyclic moiety bound to the 3-position of the pyrimidinone ring and a biphenylmethyl moiety bound to the 5-position of the pyrimidinone ring. Preferred heterocyclic moieties include furan, thiophene, thiazole, isothiazole, oxazole, isoxazole, pyridine, pyrimidine, pyrazine, and pyridazine rings.Type: GrantFiled: October 16, 1998Date of Patent: August 1, 2000Assignee: Istituto Luso Farmaco D'Italia S.p.A.Inventors: Aldo Salimbeni, Davide Poma, Renato Canevotti
-
Patent number: 5538987Abstract: Compounds of general formula (I) ##STR1## wherein E is O or S; R is C.sub.1 -C.sub.5 straight, branched or cyclic alkyl or C.sub.2 -C.sub.5 alkenyl; X can be H, F, Cl, Br, I, CF.sub.3 ; n is an integer 1 to 4; m is an integer 0 to 4; A and B are 5- or 6- membered aromatic carbocyclic rings optionally containing one or more heteroatoms selected from N, O, S and carrying the substituents R.sub.1, R.sub.2 and R.sub.3, respectively; R.sub.1 can be hydrogen, halogen, C.sub.1 -C.sub.4 alkoxycarbonyl, a sulfonic group or a tetrazole group of formula ##STR2## wherein R.sub.4 can be hydrogen or C.sub.1 -C.sub.5 alkyl; R.sub.2 can be hydrogen or a COOR.sub.4 group (wherein R.sub.4 is hydrogen or C.sub.1 -C.sub.5 alkyl), CN, SO.sub.3 H, PO.sub.3 H or a tetrazole group R.sub.3 ; can be a hydrogen or a moiety of formula (II)B'(R'.sub.2,R'.sub.3) (II)wherein: B.sup.1, R.sup.1.sub.2 have the same meanings reported above for B and R.sub.2, R'.sub.3 is H; with the proviso that when A is phenyl, R.sub.Type: GrantFiled: January 25, 1995Date of Patent: July 23, 1996Assignee: Istituto Luso Farmaco D'Italia S.p.A.Inventors: Aldo Salimbeni, Renato Canevotti, Jacques Mizrahi, Carlo Scolastico